Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Healthcare Medical Devices
Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Theralase Technologies Inc. > Going concern
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(48)
•••
Comment by langostaon Oct 04, 2022 12:42pm
273 Views
Post# 35004435

RE:Going concern

RE:Going concern
jmm1228 wrote: Seems to me that the transition from an R&D mission to a going concern is a primary investor worry. 

It worries me. There is a dearth of going concern executive talent here and no signals that this huge breakthrough can be skillfully advanced to market with the current skill set. 

 Until this fear is quelled and TLT trading moves to abmore stable exchange,the slog upwards will be tough.



Feb 15/2019 Shawn Shirazi appointed CEO of Drug Division.
Aug 20/2021 Shawn Shirazi resigns.                                             
Length of stay    approx. 2,5yrs

Feb 15/2019 Kipton Lade appointed CEO of Device Division.
Nov 1/2019   Kipton Lade resigns.
Length of stay      approx 8.5mos.

Nov 15/2021 John Trikola appointed as CEO and is let go immediately
 Length of stay.   Zero. Cause unknown.

Oct 25/2021  Dr Vera Madzarevic appointed as Clinical Developer and Quality Assurance.
Aug 30/2022  Dr Vera Madzarevic resigns.
Length of stay        approx. 10mos.

Is this normal?                    . 
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities